Cancer Research The Future of Cancer Research: Science and Patient Impact  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 38, 2325-2331, August 1, 1978]
© 1978 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klubes, P.
Right arrow Articles by Mandel, H. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klubes, P.
Right arrow Articles by Mandel, H. G.

Effects of 5-Fluorouracil on 5-Fluorodeoxyuridine 5'-Monophosphate and 2-Deoxyuridine 5'-Monophosphate Pools, and DNA Synthesis in Solid Mouse L1210 and Rat Walker 256 Tumors1

Philip Klubes, Kristine Connelly, Ingeborg Cerna and H. George Mandel

Department of Pharmacology, The George Washington University Medical Center, Washington, D. C. 20037

We have examined some of the factors determining the action of 5-fluorouracil (FUra) against a responsive and nonresponsive rodent tumor. In mice bearing the FUra-responsive solid L1210 tumor, [3H]deoxyuridine (dUrd) incorporation into tumor DNA ceased promptly after FUra (100 mg/kg i.p.), and recovery was delayed for more than 96 hr. Incorporation of [3H]dUrd into bone marrow and small intestine, which were also strongly inhibited after FUra, recovered well before that of tumor. The levels of acid-soluble 5-fluorodeoxyuridine 5'-monophosphate (FdUMP) behaved in a reciprocal manner to the rate of [3H]dUrd incorporation in the tumor, although in small intestine and bone marrow this relationship was not as evident. Appreciable levels of FdUMP persisted in L1210 tumor for up to 72 hr after FUra. The 2-deoxyuridine 5'-monophosphate pool in the tumor was increased approximately 2-fold.

In rats bearing the relatively FUra-unresponsive solid Walker 256 carcinosarcoma, the incorporation of [3H]dUrd into DNA also promptly ceased after FUra (120 mg/kg s.c.), but then it rapidly resumed its normal rate within 48 hr. The effects of FUra on [3H]dUrd incorporation in rat bone marrow and duodenum were similar to those in the tumor except that recovery of [3H]dUrd incorporation was somewhat slower than that in the tumor. The levels of acid-soluble FdUMP increased and then decreased but not in precise association with inhibition and recovery of [3H]dUrd incorporation, respectively, in all tissues studied. Although initial levels of FdUMP in tumor were high, the anabolite was no longer measurable after 48 hr. The 2-deoxyuridine 5'-monophosphate pool in tumor was increased approximately 2-fold.

The prolonged inhibition of [3H]dUrd incorporation into DNA in the responsive L1210 tumor and the more rapid recovery in the relatively insensitive Walker 256 tumor correlated with the persistence of FdUMP in the L1210 tumor and its rapid disappearance in the Walker 256 tumor, but peak levels of FdUMP did not relate to tumor susceptibility to FUra.

1 This work was supported by Grants CA 02978 and CA 17601, awarded by the National Cancer Institute, Department of Health, Education, and Welfare, Bethesda, Md., and by American Cancer Society Grant CI-110.

Received 2/ 2/78. Accepted 5/ 8/78.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
S. Pratt, R. L. Shepard, R. A. Kandasamy, P. A. Johnston, W. Perry III, and A. H. Dantzig
The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites
Mol. Cancer Ther., May 1, 2005; 4(5): 855 - 863.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1978 by the American Association for Cancer Research.